HSR Waiting Period Expires for Neurocrine's Acquisition of Soleno Therapeutics
SLNO sits 79% above its 52-week low of $29.43 on light trading volume (0.4× avg).
Summary
Soleno Therapeutics announced that the HSR Act waiting period for Neurocrine Biosciences' tender offer has expired, satisfying a key condition for the acquisition.
Key Events · M&A and Partnerships · SLNO
-
HSR Waiting Period Satisfied
The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the tender offer has expired as of April 27, 2026.
-
Key Acquisition Condition Met
This satisfies a crucial regulatory condition for Neurocrine Biosciences' tender offer to acquire Soleno Therapeutics, moving the deal closer to completion.
Analysis · SLNO · Life Sciences
This amendment confirms the satisfaction of a critical regulatory condition for Neurocrine Biosciences' tender offer to acquire Soleno Therapeutics. The expiration of the Hart-Scott-Rodino Act waiting period removes a significant hurdle, bringing the acquisition closer to completion. Investors should view this as a positive development, indicating the deal is progressing as planned and reducing regulatory risk.
At the time of this filing, SLNO was trading at $52.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $29.43 to $90.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.